IRB #

STUDY00019620

Title

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

Principal Investigator

Charles Lopez

Study Purpose

To find out about the safety and good and bad effects of CPI-613 in metastatic pancreatic cancer when used in combination with FOLFIRINOX (FFX).

Medical Condition(s)

Metastatic Pancreatic Cancer
Adenocarcinoma
CPI-613
FOLFIRINOX

Eligibility Criteria

Inclusion:
- Metastatic adenocarcinoma of the pancreas
- 18-75 years of age

Exclusion:
- Prior treatment with any chemotherapy for metastatic adenocarcinoma of the pancreas

Age Range

18 - 75

Healthy Volunteers Needed

No

Duration of Participation

At least 6 months of treatment and up to 3 years follow-up.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Rafael Pharmaceuticals

Recruitment End

03/03/2025

Compensation Provided

No


Go Back